Details up front: AST · ecnoglutide.
I would like the mechanism, because I want to be able to reason about the cases nobody has written about.
I have tried to reason it out from first principles and got to two contradictory conclusions.
So what is the mechanism, and how well established is it?
Answer first: mild transaminase elevation is common in this population before any drug is involved, and the usual cause is hepatic steatosis rather than anything acute.
Reference upper limits around forty units per litre for ALT are conventional rather than physiological; several groups have argued for limits closer to thirty for men and twenty-five for women.
| Quantity | Value | Derivation |
|---|---|---|
| Control-arm event rate | 8.0 % | From the trial table, not the abstract |
| Hazard ratio | 0.80 | Reported |
| Treated event rate | 6.4 % | 8.0 × 0.80 |
| Absolute risk reduction | 1.6 pp | 8.0 − 6.4 |
| Number needed to treat | 63 | 1 ÷ 0.016 |
| Relative risk reduction | 20 % | 1 − 0.80 |
The last two rows describe the same finding. Only one of them is used in headlines.
Hy's law describes the combination that matters: transaminases above three times the upper limit together with bilirubin above twice the upper limit and no cholestatic explanation. That combination is a signal; isolated mild transaminase elevation is not.
Population data show a substantial fraction of adults with mild transaminase elevation attributable to hepatic steatosis, which sets the base rate against which any new finding should be read.
The caveat is direct: rising liver enzymes with jaundice, dark urine or right-upper-quadrant pain is a same-day clinical problem, not a forum question.
Get a baseline before you start anything, because it converts an uninterpretable result into an interpretable one for the cost of one blood draw.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsReference intervals for alanine aminotransferase differ between laboratories and have been revised downward over time, so the same value can be normal on one report and elevated on another.
Alanine aminotransferase is relatively liver-specific; aspartate aminotransferase is also present in muscle, heart and red cells. A raised AST with a normal ALT after heavy resistance training is usually muscle, and creatine kinase settles the question.
Concretely, gamma-glutamyl transferase is sensitive and unspecific: it rises with alcohol, with several medications and with fatty liver, and an isolated elevation rarely changes anything on its own.
Isolated mild elevation is common and usually improves with weight loss.
The relevant caution is that a rapid rise, particularly with bilirubin, is a different event from a stable mild elevation and needs handling differently.
Weight loss of ten per cent or more typically reduces transaminases substantially in people whose elevation was driven by hepatic fat, which is the majority of mild elevations in this population.
Creatine kinase, alkaline phosphatase and bilirubin together tell you which compartment the abnormality is in, and ordering the transaminases alone throws that information away.
Laboratory-specific reference intervals for transaminases vary enough that cross-laboratory comparison of borderline values is unreliable.
Nothing here is medical advice. An abnormal result needs somebody who can take a history and examine you.
Transaminases plus bilirubin plus alkaline phosphatase, or you have not measured enough to conclude anything.
edited 26 May 2026 by Dr_Idris_Coulibaly — clarified the distinction between purity and content
Before attributing anything to a compound, account for alcohol, muscle injury from new training, and any over-the-counter product being taken alongside.
Very rapid weight loss can transiently worsen liver biochemistry, which is one of several arguments against pursuing the steepest possible trajectory.
Attributing an enzyme change to a compound requires a baseline, and most people asking have not got one.
New training, alcohol and over-the-counter products first. Then the interesting hypotheses.
This is one of the areas where the trend across several measurements is far more informative than any single result.
An isolated result three weeks after starting anything is difficult to interpret. A baseline taken before starting makes the same result trivially interpretable, which is the argument for baselines.
Hy's law and its variants are the standard framework for identifying drug-induced liver injury in trials and are why bilirubin is measured alongside transaminases rather than instead.
Read the pattern before the magnitude, and the magnitude in multiples of the upper limit.
edited 10 Mar 2026 by fib4_reader — corrected a unit error in the worked example
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.